Literature DB >> 20859738

Neuropsychiatric manifestations associated with azithromycin in two brothers.

Elad Schiff1, K May, L H Goldstein.   

Abstract

BACKGROUND: Neurologic adverse events reported in premarketing clinical trials of azithromycin have been mild, occurring in less than 1% of the patients, and include dizziness, headache, vertigo, and somnolence. Serious adverse neuropsychiatric effects of azithromycin have never been reported in the pediatric population and only seldom in adults. CASE REPORT: We report two brothers aged 6 and 15 years with severe and prolonged complex neuropsychiatric manifestations associated with azithromycin treatment. Both brothers experienced visual and auditory hallucinations, and one brother additionally experienced multiple partial complex seizures, severe headaches, and recurrent cortical blindness. All symptoms commenced within 24 h after the initial dose of azithromycin and resolved slowly, within 2-4 weeks. DISCUSSION: Possible genetic and environmental explanations are discussed, such as polymorphism in uptake of efflux transporters at different levels, particularly at the blood brain barrier level.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20859738     DOI: 10.1007/s00228-010-0900-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  [Delirium associated with azithromycin administration].

Authors:  François Sirois
Journal:  Can J Psychiatry       Date:  2002-08       Impact factor: 4.356

2.  Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye.

Authors:  S Jaruratanasirikul; R Hortiwakul; T Tantisarasart; N Phuenpathom; S Tussanasunthornwong
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

3.  Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function.

Authors:  S Laechelt; E Turrini; A Ruehmkorf; W Siegmund; I Cascorbi; S Haenisch
Journal:  Pharmacogenomics J       Date:  2010-03-30       Impact factor: 3.550

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 5.  Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.

Authors:  Elaine M Leslie; Roger G Deeley; Susan P C Cole
Journal:  Toxicol Appl Pharmacol       Date:  2005-05-01       Impact factor: 4.219

Review 6.  Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.

Authors:  Ingolf Cascorbi
Journal:  Pharmacol Ther       Date:  2006-11       Impact factor: 12.310

Review 7.  Impact of OATP transporters on pharmacokinetics.

Authors:  A Kalliokoski; M Niemi
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

8.  Delirium in the elderly resulting from azithromycin therapy.

Authors:  Lawrence A Cone; Lester Padilla; Barbara E Potts
Journal:  Surg Neurol       Date:  2003-06

9.  Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides.

Authors:  Tian Lan; Anuradha Rao; Jamie Haywood; Charles B Davis; Chao Han; Eric Garver; Paul A Dawson
Journal:  Drug Metab Dispos       Date:  2009-09-09       Impact factor: 3.922

10.  Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat.

Authors:  Eric Garver; Erin D Hugger; Shawn P Shearn; Anuradha Rao; Paul A Dawson; Charles B Davis; Chao Han
Journal:  Drug Metab Dispos       Date:  2008-08-28       Impact factor: 3.922

View more
  2 in total

1.  Erythromycin Induced Nightmares.

Authors:  Maria E Møller; Qasim Aziz; Jacob Juel
Journal:  J Neurogastroenterol Motil       Date:  2016-07-30       Impact factor: 4.924

2.  Predicting neurological Adverse Drug Reactions based on biological, chemical and phenotypic properties of drugs using machine learning models.

Authors:  Salma Jamal; Sukriti Goyal; Asheesh Shanker; Abhinav Grover
Journal:  Sci Rep       Date:  2017-04-13       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.